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ABSTRACT N-methyl-D-aspartate (NMDA) receptor antagonists, such as ketamine, have emerged as
novel candidate treatments for major depressive disorder, but abuse potential of these agents is a
concern. The NMDA antagonist phencyclidine has known abuse liability but undefined efficacy as
an antidepressant. To further evaluate the relationship between antidepressant-like and abuse-related
effects of NMDA antagonists, this study evaluated the effects of phencyclidine (1.0–10.0 mg/kg) in male
Sprague-Dawley rats responding under two procedures that have been used to assess antidepressant-
like effects (differential-reinforcement-of-low-rate [DRL] 72 s schedule of food reinforcement; n = 9)
and abuse-related drug effects (intracranial self-stimulation [ICSS]; n = 6). Under the DRL 72 s
schedule, phencyclidine (10.0 mg/kg) increased reinforcers and decreased responses without shifting
the peak location of the interresponse time (IRT) distribution. Ketamine (10.0 mg/kg) also increased
reinforcers and decreased responses, but unlike phencyclidine, it produced a rightward shift in the
peak location of the IRT distribution. The 10.0 mg/kg phencyclidine dose that decreased DRL 72 s
responding also decreased rates of ICSS for 50 min after its administration; however, abuse-related ICSS
facilitation was observed at later times (100–300 min) or after a lower phencyclidine dose (3.2 mg/kg).
These results suggest that phencyclidine produces weaker antidepressant-like effects, but stronger abuse-
related effects than ketamine in these procedures. Drug Dev Res 75 : 479–488, 2014. © 2014 Wiley
Periodicals, Inc.
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INTRODUCTION
Over the past decade, glutamatergic systems have
emerged as a potential target for treating major depres-
sive disorder (MDD). Specifically, drugs that target and
antagonize the N-methyl-D-aspartate (NMDA) recep-
tor complex can be a successful treatment for patients
suffering from MDD [Berman et al. 2000; Zarate et al.,
2006; Preskorn et al., 2008; Murrough et al., 2013a,
2013b; Zarate et al., 2013]. For example, the noncom-
petitive NMDA receptor antagonist, ketamine, which
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has shown the most promise, produces rapid and sus-
tained antidepressant effects following subanesthetic
intravenous infusion in patients suffering from MDD
[Berman et al. 2000; Zarate et al., 2006; Murrough
et al., 2013a, 2013b]. However, the abuse liability of
NMDA antagonists, such as ketamine, is a concern
[McCambridge et al., 2007; Shek, 2007; Substance
Abuse and Mental Health Services Administration,
2013].
The relationship between the antidepressant and
abuse-related effects of NMDA antagonists has not
been defined. In preclinical studies, the high-affinity
and selective noncompetitive NMDA receptor antago-
nist, MK-801, typically serves as a useful comparator to
ketamine [Maeng et al., 2008; Autry et al., 2011; Koike
et al., 2011]; however, we recently reported dissociable
antidepressant-like and abuse-related effects of
ketamine andMK-801. Specifically, ketamine produced
an antidepressant-like profile in rats responding under a
differential-reinforcement-of-low-rate (DRL) 72 s
schedule of reinforcement; whereas, MK-801 produced
a stimulant-like profile [Hillhouse and Porter, 2014].
Conversely, ketamine failed to produce an abuse-
related facilitation of intracranial self-stimulation
(ICSS) under a number of conditions; whereas,
MK-801 produced a stimulant-like facilitation of ICSS
[Hillhouse and Porter, 2014; Hillhouse et al., 2014].
These results were interpreted to suggest stronger
antidepressant-like effects, but weaker abuse-related
effects for ketamine relative to MK-801.
Phencyclidine is another drug with NMDA
antagonist effects [Bresink et al., 1995] and known
abuse liability [Olthuis et al., 2013; Substance Abuse
and Mental Health Services Administration, 2013], but
possible antidepressant-like effects of phencyclidine
have not been fully evaluated. Ketamine is a derivative
of phencyclidine, and thus, it is possible that phencycli-
dine may produce antidepressant-like effects similarly
to ketamine. While other NMDA antagonists like
ketamine, MK-801, and memantine have been thor-
oughly evaluated in several preclinical procedures used
to screen antidepressant drugs, only a single study has
evaluated the effects of phencyclidine in the forced
swim test in which treatment with 15.0 mg/kg did not
display an antidepressant-like effect [Turgeon et al.,
2007]. The limited preclinical and clinical literature on
the possible antidepressant effects of phencyclidine
warrants further preclinical evaluations. The DRL 72 s
is an operant procedure that provides high predictive
validity for screening novel antidepressant drugs.
Under the DRL 72 s schedule, in which animals are
reinforced only for responses that are emitted 72 s after
the last lever press, clinically efficacious antidepressant
drugs will increase reinforcers, decrease responses, and
produce a rightward shift in the peak location of the
interresponse time (IRT) distribution (for full review
see O’Donnell et al. [2005]). The DRL 72 s procedure
has been used since the 1980s as a tool to reliably screen
antidepressant. For example, antidepressant drugs such
as monoamine oxidase inhibitors, tricyclic antidepres-
sants, and selective serotonin reuptake inhibitors
(SSRI) produce antidepressant effects in the DRL 72 s
task, while drugs from other pharmacological classes
such as morphine and alcohol do not produce
antidepressant-like effects [O’Donnell and Seiden,
1982, 1983; Sokolowski and Seiden, 1999].
ICSS is a family of procedures used to reliably
assess and compare the abuse liability of drugs in which
animals are trained to lever press for brain stimulation
[Kornetsky et al., 1979; Carlezon and Chartoff, 2007;
Negus and Miller, 2014]. Specifically, the “frequency-
rate” ICSS procedure manipulates the frequency of
brain stimulation while maintaining a constant stimula-
tion intensity. The frequency-rate procedure engenders
a broad range of baseline ICSS rates, and is sensitive to
drug effects on both low and high ICSS rates. Most
drugs of abuse will increase low ICSS rates maintained
at low stimulation frequencies, and this is typically
interpreted as an abuse-related “facilitation” of ICSS
[Wise et al., 1992; Negus and Miller, 2014]. Moreover,
drugs can decrease high ICSS rates maintained at high
stimulation frequencies, and this is typically interpreted
as abuse-limiting depression of ICSS [Negus and
Miller, 2014]. Phencyclidine has been previously tested
twice under frequency-rate procedure; however, the
dose range (i.e., 2.5–5.0 mg/kg) and pretreatment time
was limited [Wise et al., 1992; Carlezon and Wise,
1993].
To address these limitations, the present study
compared the antidepressant-like effects of the non-
competitive NMDA receptor antagonists phencyclidine
and ketamine using the DRL 72 s procedure. Addition-
ally, the frequency-rate ICSS procedure was used to
evaluate the dose- and time-dependent abuse-related
effects of phencyclidine because this procedure is sen-
sitive to both the abuse-related and abuse-limiting
effects of drugs.
MATERIALS AND METHODS
Animals
Fifteen adult male Sprague-Dawley rats (Harlan
Laboratories Inc, Frederick, MD, USA) were used in
the DRL 72 s and ICSS experiments, and weighed
between 300 and 350 g at the start of experiments. All
rats were housed individually in plastic rodent cages in
the vivarium on a 12 h light/dark cycle (lights on
0600 h). After acclimation to the vivarium, the nine rats
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in the DRL experiment were given restricted access to
food (Harlan Teklad Lab Diets, Teklad LM-485) to
maintain them at 85% of their free feeding body
weights. The six rats in the ICSS experiment had free
access to food. All rats had free access to water while in
their home cage. Procedures complied with the Guide
for the Care and Use of Laboratory Animals [Institute
of Laboratory Animal Resources, 2011] and were
approved by the Virginia Commonwealth University
Institutional Animal Care and Use Committee.
DRL
DRL training and test sessions were identical to
those described previously for studies with ketamine
and MK-801 [Hillhouse and Porter, 2014]. The DRL
experiment was conducted in four operant condition-
ing chambers (Model ENV-008-VP, Med Associates,
St. Albans, VT, USA) equipped with a retractable
response lever, house light, and pellet dispenser for
delivery of 45 mg purified diet pellets (Product
#F0021, Bio-Serv, Frenchtown, NJ, USA). The house
light was on for the duration of all training and testing
sessions, which lasted 60 min. During initial training
sessions, rats were trained to lever press for food rein-
forcement under a fixed-ratio 1 (FR 1), and these train-
ing sessions concluded after 50 reinforcers were earned
or 60 min. Following completion of lever press train-
ing, rats started DRL training in which a reinforcer
(i.e., pellet) was delivered if the rat withheld a response
for the specified interresponse interval. If a response
was emitted prior to the termination of the inter-
response interval, the interresponse timer was reset,
and no pellet was delivered. The interresponse interval
was increased over 28 sessions starting with 4.5 s and
ending with the final interresponse interval of 72 s.
Rats met training criteria when the number of
responses per session for each rat varied by ≤10% of
the mean for five of six consecutive sessions. Test ses-
sions with phencyclidine (1.0–10.0 mg/kg; 30 min)
were conducted twice a week (typically Tuesday and
Friday), with one training session before each test
session. Ketamine (1.0–10.0 mg/kg; 10 min) was also
studied as a positive control. A saline baseline was
determined for each drug. Drug and dose order were
administered by Latin-square design.
For the DRL experiment, there were three
dependent variables: (i) total number of reinforcers
earned; (ii) total number of responses emitted; and (iii)
IRTs for all responses. Reinforcer, response, and IRT
data were analyzed using one-way repeated-measures
analysis of variance (ANOVA), with drug dose treated as
the within-subjects factor. IRT distributions were
obtained by recording responses in 25 6 s bins, with the
first 6 s bin representing “burst responding.” A peak
location analysis was performed to assess significant
shifts in the IRT distributions [Richards et al., 1993;
Hillhouse and Porter, 2014]. Specifically, the median of
the IRT distribution for each individual rat was deter-
mined after eliminating burst responses from the total
number of responses, and the medians (peak location)
were then analyzed using one-way repeated-measures
ANOVA. Holm–Sidak post hoc tests were conducted
after all significant ANOVAs. ICSS and DRL data were
analyzed using GraphPad Prism version 6.0 (GraphPad
Software, San Diego, CA, USA), and the criterion for
significance was set at P < 0.05.
ICSS
ICSS surgeries, training, and test sessions were
identical to those described previously for studies with
ketamine and MK-801 [Hillhouse et al., 2014]. Briefly,
rats were anesthetized with isoflurane gas (2.5–3% in
oxygen; Webster Veterinary, Phoenix, AZ, USA) for
implantation of stainless-steel electrodes. The cathode
of each electrode (Plastics One, Roanoke, VA, USA)
was 0.25 mm in diameter and covered with polyamide
insulation, except at the flattened tip. The anode was
0.124 mm in diameter and uninsulated. The cathode
was implanted in the left medial forebrain bundle at the
level of the lateral hypothalamus (2.8 mm posterior and
1.7 mm lateral from the bregma, and 8.8 mm below the
skull) [Pereira Do Carmo et al., 2009]. The anode was
wrapped around one of three skull screws to serve as
the ground, and the skull screws and electrode assembly
were secured with orthodontic resin. Rats received
ketoprofen (5 mg/kg i.p. for 2 days) as a postoperative
analgesic and were allowed to recover for at least 7 days
before commencing ICSS training.
ICSS experiments were conducted in six sound-
attenuating chambers that contained operant condi-
tioning chambers (Model ENV-007-VP-CT, Med
Associates) equipped with a single response lever,
stimulus lights, house light, and an ICSS stimulator
(Model SG-510, Med Associates) for delivery of brain
stimulation. The house light was illuminated during
behavioral sessions, and lever-press responding under a
FR 1 schedule produced a 0.5 s train of 100 μs square-
wave cathodal pulses and concurrent illumination of
stimulus lights over the response lever. The terminal
schedule consisted of sequential 10 min components.
During each component, a descending series of 10
current frequencies was presented, with a 60 s trial at
each frequency, and the available frequency decreased
from 158 to 56 Hz in 0.05 log unit steps during the 10
trial components. Each frequency trial consisted of a
10 s “timeout” followed by a 50 s “response” period.
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During the “time out,” five noncontingent electrical
brain stimulations were delivered to the rat at the fre-
quency available during that trial, and lever-press
responding had no consequence. During this
“response” period, responding under the FR 1 schedule
produced electrical brain stimulation at the same fre-
quency that was delivered during the 10 s “timeout.”
Training continued until rates exceeded 50% maximum
control rates for the first three to six trials for three
sequential components for at least three consecutive
days. Training concluded with habituation to saline
injections until there were no significant injection
effects on ICSS frequency-rate curves.
ICSS test sessions for dose-effect testing consisted
of five sequential components. The first component of
each test session was considered an acclimation compo-
nent, and data from this component were discarded.
Data from the second and third components were con-
sidered “baseline components” and were used to calcu-
late control parameters of frequency-rate curves for
that test session in that rat (see below). Immediately
after completion of the baseline components, a dose of
phencyclidine (1.0–10.0 mg/kg) was administered
intraperitoneally, and after the designated pretreat-
ment time of 30 min, ICSS was evaluated during two
test components (10 min each, 20 min total). Testing
was conducted twice per week (typically Tuesday and
Friday). Dose order was administered using a Latin-
square design. Additional studies were conducted to
investigate the time course of effects produced by
10.0 mg/kg phencyclidine. For time-course studies,
baseline components were conducted as above. Rats
were then immediately injected with phencyclidine,
and pairs of ICSS test components were initiated 10, 30,
100, and 300 min after the injection. Saline has been
tested previously using this time-course procedure
(e.g., Altarifi et al. [2012]), and ICSS rates were stable
across all time points.
For ICSS experiments, the primary dependent
variable was reinforcement rate (i.e., stimulations per
minute during each frequency trial). To normalize
these data, raw reinforcement rates from each trial in
each rat were converted to percent maximum control
rate (%MCR), with MCR defined as the mean of the
maximal rates observed during the second and third
baseline components for any given rat in any given
session. Thus, %MCR values for each trial were calcu-
lated as %MCR = (reinforcement rate during a fre-
quency trial ÷ maximum control rate) × 100. For each
experimental manipulation, data from all test compo-
nents were averaged first within each rat and then
across rats to yield mean test curves for each manipu-
lation. Data were analyzed using two-way repeated
measures ANOVA, with drug dose or time as one
factor and ICSS frequency as the other factor. Holm–
Sidak post hoc test were conducted after all significant
ANOVAs (see Hillhouse and Porter [2014]; Hillhouse
et al. [2014] for complete description of data analysis).
The total number of stimulations delivered across all
10 frequency trials was determined for each compo-
nent and was used to provide a summary of ICSS per-
formance. The average number of total stimulations
per test component was expressed as a percentage of
the average number of total stimulations per compo-
nent during the second and third baseline components
(% baseline).
Drugs
Phencyclidine HCl (Sigma Aldrich, St. Louis,
MO, USA) and (±) ketamine HCl (Sigma) were dis-
solved in 0.9% physiological saline. Drugs were
administered intraperitoneally at a volume of 1.0 mL/
kg. Doses and pretreatment times for phencyclidine
(1.0–10.0 mg/kg, 30 min) and ketamine (1.0–10.0 mg/
kg, 5 min) were based on preliminary and previous
studies [Schaefer and Michael, 1990; Wise et al.,
1992; Carlezon and Wise, 1993; Hillhouse and Porter,
2014].
RESULTS
Figure 1 compares the effects of phencyclidine
and ketamine on DRL 72 s performance. The 1.0 and
3.2 mg/kg dose of phencyclidine did not significantly
alter the number of reinforcers earned or number of
responses emitted; whereas the dose of 10.0 mg/kg
phencyclidine significantly increased reinforcers
(F3,24 = 7.77, P < 0.001; Figure 1A) and significantly
decreased the number of responses (F3,24 = 4.64,
P < 0.05; Figure 1B). Phencyclidine (1.0–10.0 mg/kg)
did not produce a significant shift in the peak location of
the IRT distribution (F3,24 = 2.44, P > 0.05; Figure 1C).
For comparison, treatment with 1.0 and 3.2 mg/kg
ketamine did not significantly affect the number of rein-
forcers earned or the number of responses emitted;
whereas, treatment with 10.0 mg/kg ketamine signifi-
cantly increased the number of reinforcers earned
(F3,24 = 9.90, P < 0.001; Figure 1D) and decreased the
number of responses emitted (F3,24 = 13.87, P < 0.001;
Figure 1E). In contrast to phencyclidine, the
10.0 mg/kg dose of ketamine produced a significant
rightward shift in the peak location of the IRT distribu-
tion (F3,24 = 3.57, P < 0.05; Figure 1F).
Figure 2 shows the effects of phencyclidine
effects on ICSS. The mean ± standard error of the
mean (SEM) MCR was 57.73 ± 2.62 stimulation per
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trial, and the mean total stimulation per component
delivered across all frequencies was 279.5 ± 24.71. Fol-
lowing saline treatment, brain stimulation maintained a
frequency-dependent increase in ICSS rates. Phency-
clidine produced mixed rate-increasing and rate-
decreasing effects that depended on both dose and
frequency of brain stimulation. Phencyclidine produced
a significant main effect of frequency (F9,45 = 70.74,
Fig. 1. Effects of phencyclidine and ketamine on DRL 72 s. Left panels (A,D) show drug effects on number of reinforcers earned.
Abscissae indicate drug dose. Ordinates indicate number of reinforcers. Center panels (B,E) show drug effects on number of responses
emitted. Abscissae indicate drug dose. Ordinates indicate number of responses. Right panels (C,F) show drug effects on interresponse time
(IRT) distribution. Abscissae indicate interresponse time. Ordinates indicate the relative frequency of responses. Filled points represent
significant shifts in peak location after drug treatment as determined by peak location analysis followed by a Holm-Sidak post hoc test,
P < 0.05. Reinforcers and responses are expressed as means ± SEM for nine rats. IRT data are expressed as means for nine rats. *P < 0.05,
***P < 0.001 versus saline.
Fig. 2. Dose effects for phencyclidine on ICSS. Left panel (A) shows dose effects of phencyclidine on full ICSS frequency-rate curve. Doses are
indicated in legends. Abscissa indicates frequency of electrical brain stimulation (Hz) (log scale). Ordinate indicates percent maximum control
reinforcement rate (%MCR). Filled points represent frequencies at which ICSS rates after drug treatment were significantly different from vehicle
rates as determined by a two-way ANOVA followed by a Holm–Sidak post hoc test, P < 0.05. Right panel (B) shows summary ICSS data
expressed as percent baseline total stimulations delivered across all frequencies of brain stimulation per test component. Abscissa indicates drug
dose (mg/kg). Ordinate indicates percent baseline stimulations per test component. Upward/downward arrows indicate significant drug-induced
increase/decrease in ICSS relative to saline for at least one brain stimulation frequency as determined by analysis of full frequency-rate curves
in the left panels. All data show mean ± SEM for six rats. ANOVA, analysis of variance; ICSS, intracranial self-stimulation; SEM, standard error
of the mean.
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P < 0.001), dose (F3,15 = 24.91, P < 0.001) and signifi-
cant interaction (F27,135 = 6.64, P < 0.001). Treatment
with 1.0 mg/kg phencyclidine did not significantly alter
ICSS rates. The intermediate dose of phencyclidine,
3.2 mg/kg, significantly increased ICSS at one fre-
quency (100 Hz); whereas the high dose of phen-
cyclidine, 10.0 mg/kg, significantly decreased ICSS at
six of the seven highest frequencies (79–158 Hz)
(Figure 2A,B). Figure 3 shows the time-course effects
of phencyclidine effects on ICSS. Phencyclidine
(10.0 mg/kg) produced significant main effect of fre-
quency (F9,45 = 54.25, P < 0.001), time (F4,20 = 12.20,
P < 0.001), and significant interaction (F36,180 = 9.83,
P < 0.001). Treatment with 10 mg/kg phencyclidine
produced a significant decrease in ICSS rates from
10–30 min and 30–50 min across a range of intermedi-
ate and high frequencies (89–158 Hz), but increased
ICSS rates at 100–120 min (56–71 and 100 Hz) and
300–320 min (63 Hz) (Figure 3A,B).
DISCUSSION
The present study is the first to report on the
antidepressant-like effects of phencyclidine using the
DRL 72 s procedure, and only the second study to
evaluate the preclinical antidepressant-like effects of
phencyclidine. While the 10.0 mg/kg dose of phencycli-
dine increased reinforcers and decreased responses, it
did not produce a rightward shift in the peak location of
the IRT distribution. These phencyclidine effects are
similar to effects of some SSRIs, which increase rein-
forcement rate and decrease response rate, but tend to
not significantly shift the peak location of the IRT distri-
butions [Sokolowski and Seiden, 1999; O’Donnell et al.,
2005]; these effects are interpreted as a partial
antidepressant-like effect. Ketamine produced effects
similar to other antidepressants, such as tricyclic antide-
pressants andmonoamine oxidase inhibitors, which con-
sistently increase reinforcement rate, decrease response
rate, and shift the peak location of the IRT distributions
to the right [O’Donnell and Seiden, 1983; vanHest et al.,
1992; O’Donnell et al., 2005; Hillhouse and Porter,
2014]; these behavioral effects are interpreted as an
antidepressant-like effect. The DRL 72 s behavioral
effects produced by phencyclidine and ketamine differ
from effects of the other noncompetitive NMDA
antagonist MK-801. MK-801 produces a stimulant-like
behavioral profile inDRL72 s, which is characterized by
a decrease in reinforcers, increase in responses, and a
leftward shift in the peak location of the IRT distribution
[Ardayfio et al., 2008;Hillhouse andPorter, 2014]. Thus,
in the DRL 72 s procedure, the effects of phencyclidine
were more similar to those of ketamine than to MK-
801, although phencyclidine failed to produce the
antidepressant-like rightward shift in the peak location
of the IRT distribution.
The antidepressant-like effects of phencyclidine
and ketamine in the DRL 72 s procedure are consis-
tent with other preclinical studies evaluating the
antidepressant-like effects of NMDA antagonists like
ketamine and memantine. For example, acute adminis-
tration of ketamine and memantine produces an
antidepressant-like reduction in time spent immobile in
the forced swim test in rats [Moryl et al., 1993; Engin
et al., 2009; Réus et al., 2010; Gigliucci et al., 2013] and
mice [Maeng et al., 2008; Autry et al., 2011]. Addition-
ally, a single acute injection of ketamine produces
antidepressant-like effects in the learned helplessness
Fig. 3. Time course of effects produced by 10.0 mg/kg phencyclidine. Left panel (A) shows phencyclidine effects on full ICSS frequency-rate
curves. Time points are indicated in legends. Filled points represent frequencies at which ICSS rates after drug treatment were significantly
different from baseline rates as determined by a two-way ANOVA followed by a Holm–Sidak post hoc test, P < 0.05. Right panel (B) shows
summary ICSS data expressed as percent baseline total stimulations delivered across all frequencies of brain stimulation per test component.
Abscissae indicate time (min). Ordinates indicate percent baseline stimulations per test component. Upward/downward arrows indicate
significant drug-induced increase/decrease in ICSS relative to saline for at least one brain stimulation frequency as determined by analysis of full
frequency-rate curves in the left panels. Other details as in Figure 2. All data show mean ± SEM for six rats. %MCR, maximum control
reinforcement rate; ANOVA, analysis of variance; ICSS, intracranial self-stimulation; SEM, standard error of the mean.
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procedure by reducing the number of escape failures in
rats [Koike et al., 2011] and mice [Maeng et al., 2008],
which is a procedure that typically requires repeated
administration of monoamine-based antidepressant
drugs. Furthermore, ketamine produced sustained
(>24 h pretreatment time) antidepressant-like effects in
the forced swim test and chronic unpredictable stress
procedure [Maeng et al., 2008; Li et al., 2010; Autry
et al., 2011; Gigliucci et al., 2013]. In contrast to the
antidepressant-like effects of phencyclidine in the
present study and the sustained antidepressant-like
effects of ketamine, a higher phencyclidine dose
(15.0 mg/kg) did not alter time spent immobile in the
forced swim test in rats tested with a 24 h pretreat-
ment time, suggesting that phencyclidine does not
produce a sustained antidepressant-like effect in the
forced swim test; however, it is important to note that
a single dose was tested and the primary aim of that
study was to use a high-dose phencyclidine to assess
the negative symptoms of schizophrenia [Turgeon
et al., 2007].
The ICSS results from the present study are con-
sistent with previous studies showing that phencycli-
dine increased rates and/or decreased threshold of
ICSS maintained under FR 1 schedule of reinforce-
ment in ICSS procedures that manipulate frequency of
brain stimulation [Wise et al., 1992; Carlezon and Wise,
1993] or intensity of brain stimulation [Kornetsky et al.,
1979; Spielewoy and Markou, 2003], respectively;
however, the 10.0 mg/kg dose of phencyclidine, which
had not been previously tested in frequency-rate ICSS,
decreased rates in the present study. The present study
extended previous findings by testing a 10-fold dose
range of phencyclidine and providing the time course of
phencyclidine effects on ICSS. Specifically, an interme-
diate phencyclidine dose (3.2 mg/kg) produced weak
but exclusive facilitation of ICSS in the dose-effect
study. The higher phencyclidine dose (10.0 mg/kg) ini-
tially depressed ICSS, which was consistent with
reduced response rates seen in the DRL 72 s proce-
dure; however, ICSS facilitation was apparent at later
time points (100–320 min) after the behavioral disrup-
tion subsided. These phencyclidine effects are similar
to the dose- and time-dependent facilitation of ICSS by
MK-801, but contrast with the finding that ketamine
only depressed ICSS [Hillhouse and Porter, 2014;
Hillhouse et al., 2014]. Thus, in the ICSS procedure,
phencyclidine effects were more similar to those of
MK-801 than to ketamine.
Fixed-interval (FI) schedules of reinforcement
also engender a wide range of response rates with low
rates of behavior occurring during the early portion of
the interval and high rates occurring toward the end of
the interval, which is similar to the baseline behavior
produced by frequency-rate ICSS, and provide a base-
line rate of behavior that is a useful comparison for
frequency-rate ICSS [Bauer et al., 2013a]. The ICSS
results from the present study are consistent with the
effects of phencyclidine on behavior maintained under
FI schedules of reinforcement. Low doses of phency-
clidine consistently increase low rates of responding
maintained under FI schedules of reinforcement in
nonhuman primates [Brady et al., 1980; Byrd, 1982],
rats [Segal et al., 1981; Wagner et al., 1984], and mice
[Wenger and Dews, 1976]; whereas high doses of phen-
cyclidine consistently decrease rates under FI sched-
ules of reinforcement [Wenger and Dews, 1976; Brady
et al., 1980; Segal et al., 1981; Byrd, 1982; Wagner
et al., 1984]. For example, in rhesus monkeys respond-
ing under a fixed-interval 5-min schedule, phencycli-
dine produced a modest increase in low rates of
behavior, shown with rate-dependency plots, at low
doses of phencyclidine. The time course of effects for
phencyclidine in rhesus monkeys responding under the
FI 5-min schedule is consistent with those in the
present study where the high dose of phencyclidine
depressed responding initially (5–60 min) and recov-
ered to control rates by 100 min [Brady et al., 1980]. It
has also been shown that low and intermediate doses of
phencyclidine produce a modest increase of low rates in
rats responding under an FI 90 s schedule [Wagner
et al., 1984].
ICSS is typically used as a behavioral procedure
to assess the abuse liability of drugs, and specifically,
the frequency-rate procedure used in the present
study provides an evaluation of both the abuse-related
and abuse-limiting effects of drugs [Kornetsky et al.,
1979; Wise, 1996; Carlezon and Chartoff, 2007; Negus
and Miller, 2014]. In the present study, phencyclidine
produced a dose- and time-dependent abuse-related
facilitation of ICSS that is consistent with other
preclinical procedures used to assess the abuse liability
of drugs. For example, phencyclidine maintains self-
administration in nonhuman primates [Marquis and
Moreton, 1987; Beardsley et al., 1990; Carroll et al.,
1994, 2000; Newman et al., 2007, 2008; Nicholson
et al., 2007], rats [Collins et al., 1983; Marquis et al.,
1989; Carlezon and Wise, 1996], and dogs [Risner,
1982]. While phencyclidine is known to possess abuse
liability, the illicit use of the drug is relatively low
compared with other drugs of abuse (e.g., marijuana
and stimulants) [Olthuis et al., 2013; Substance
Abuse and Mental Health Services Administration,
2013]. In addition to producing abuse-related faci-
litation of ICSS in the present study, phencyclidine
also produced abuse-limited depression of ICSS,
which is consistent with the relatively low illicit use of
phencyclidine.
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In conclusion, the results from the present study
add to an emerging body of literature evaluating
antidepressant-like and abuse-related effects of NMDA
receptor antagonists in preclinical behavioral models.
Specifically, our findings provide further evidence
that expression of these effects may be related to
NMDA receptor affinity. For example, the low-
affinity antagonist ketamine (Ki = 1,190 nM) produces
antidepressant-like effects in the DRL 72 s procedure
with little evidence from ICSS procedures for abuse
potential, whereas the high-affinity antagonist MK-801
(Ki = 2.5 nM) fails to produce antidepressant-effects in
the DRL 72 s procedure, but does produce abuse-
related facilitation of ICSS [Bresink et al., 1995;
Hillhouse and Porter, 2014; Hillhouse et al., 2014]. In
comparison with ketamine and MK-801, phencycli-
dine has intermediate affinity at NMDA receptors
(Ki = 42 nM) [Bresink et al., 1995] and it produced a
mixed profile of behavioral effects that included both
partial antidepressant-like effects in the DRL 72 s pro-
cedure and abuse-related facilitation of ICSS. While
the present preclinical results provide evidence that
phencyclidine may produce antidepressant-like effects,
it is unlikely that phencyclidine will be tested in clinical
settings because of abuse liability concerns.
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